gabapentin has been researched along with Bipolar Disorder in 113 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabapentin might provide some benefit on the long-term outcome of bipolar disorder." | 9.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder." | 9.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 8.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "From the data presented, gabapentin cannot be recommended for treatment of bipolar disorder." | 8.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 8.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 8.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| " We evaluated a nationwide sample to determine whether the $430 million gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin market share, substitution of other scientifically substantiated and unsubstantiated anticonvulsants, and anticonvulsant spending of Medicare/Medicaid patients diagnosed with bipolar disorder." | 7.78 | Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. ( Chace, MJ; Fullerton, CA; Gilden, D; Huskamp, HA; Soumerai, SB; Zhang, F, 2012) |
| " The case of gabapentin use in bipolar disorder provides an opportunity to study the roles of marketing, clinical evidence, and prior authorization (PA) policy on off-label medication use." | 7.76 | The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. ( Busch, AB; Frank, RG; Fullerton, CA, 2010) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 7.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 7.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "To evaluate the efficacy of gabapentin as an adjunctive treatment for bipolar disorder in both depressed and manic phases." | 7.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 7.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 7.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| "Gabapentin was well tolerated by all patients, with the most common side-effect being sedation." | 6.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| " Open reports suggest usefulness of gabapentin as an adjunct in bipolar disorder, but double-blind trials failed to confirm efficacy in acute mania and treatment-resistant rapid-cycling bipolar disorder." | 6.20 | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. ( Calabrese, JR; Kroeker, G; Kusumakar, V; Rao, R; Scarrow, G; Yatham, LN, 2002) |
| "Open studies and case observations have suggested that gabapentin may be effective in the treatment of bipolar disorder." | 6.19 | Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. ( Akiskal, H; Perugi, G; Ruffolo, G; Sartini, S; Simonini, E; Toni, C, 1999) |
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Disrupted brain gamma-aminobutyric acid (GABA)/glutamate homeostasis is a promising target for pharmacological intervention in co-occurring bipolar disorder (BD) and cannabis use disorder (CUD)." | 5.51 | Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. ( Arnold, L; Hix, S; Mellick, W; Prisciandaro, JJ; Squeglia, LM; Tolliver, BK, 2022) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 5.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| "Gabapentin is a relatively new anticonvulsant indicated for adjunctive therapy in the treatment of partial seizures, with and without secondary generalization, in adults with epilepsy." | 5.31 | Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin. ( Brannon, GE; Rolland, PD, 2000) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 5.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "In this clinical trial, we studied the effects of adjunctive treatment with gabapentin in controlling the symptoms of acute mania in patients admitted with bipolar disorder." | 5.16 | Adjunctive treatment with gabapentin in bipolar patients during acute mania. ( Astaneh, AN; Rezaei, O, 2012) |
| "This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabapentin might provide some benefit on the long-term outcome of bipolar disorder." | 5.12 | A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. ( Colom, F; Comes, M; Manuel Goikolea, J; Martínez-Arán, A; Masramon, X; Sanchez-Moreno, J; Verger, K; Vieta, E, 2006) |
| "Gabapentin (GBP) may be useful in bipolar disorders, including as adjunctive therapy for bipolar depression, although controlled studies suggest inefficacy as primary treatment for mania or treatment-resistant rapid cycling." | 5.10 | Gabapentin augmentation therapy in bipolar depression. ( Ketter, TA; Santosa, C; Schumacher, M; Strong, C; Wang, PW; Winsberg, ME, 2002) |
| "Anticonvulsant agents such as carbamazepine and valproate are alternatives to lithium in treating subjects with bipolar disorder." | 5.09 | Topiramate as add-on treatment for patients with bipolar mania. ( Atzert, R; Brar, JS; Chengappa, KN; Delaney, J; Levin, H; Levine, J; Moffa, N; Parepally, H; Rathore, D; Solai, L, 1999) |
| "The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder." | 5.09 | Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. ( Crockatt, JG; Janney, CA; Pande, AC; Tsaroucha, G; Werth, JL, 2000) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 4.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| " Despite the generally weak study design in the identified publications, the authors of the articles often commented on the promising nature of gabapentin therapy for bipolar disorder." | 4.84 | Gabapentin in the treatment of mental illness: the echo chamber of the case series. ( Carey, TS; Goodman, F; Melvin, CL; Morgan, LC; Oldham, JM; Ranney, LM; Whitener, L; Williams, JW, 2008) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "The role of lithium carbonate in the maintenance treatment of bipolar disorder is well established." | 4.82 | Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. ( Freeman, MP; Gelenberg, AJ; Gnanadesikan, M, 2003) |
| "From the data presented, gabapentin cannot be recommended for treatment of bipolar disorder." | 4.81 | Gabapentin treatment for bipolar disorders. ( Maidment, ID, 2001) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 4.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 4.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "The aims of this study were to assess the association between gabapentin and suicidality in patients diagnosed with bipolar disorder (BD) and to determine whether the risk is greater relative to patients prescribed lithium." | 3.91 | The association between gabapentin and suicidality in bipolar patients. ( Boehnlein, JK; Freeman, MD; Lambert, WE; Leith, WM, 2019) |
| "Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS)." | 3.79 | Lamotrigine in the treatment of bipolar depression. ( Bowden, CL; Mitchell, P; Suppes, T, 1999) |
| " We evaluated a nationwide sample to determine whether the $430 million gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin market share, substitution of other scientifically substantiated and unsubstantiated anticonvulsants, and anticonvulsant spending of Medicare/Medicaid patients diagnosed with bipolar disorder." | 3.78 | Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. ( Chace, MJ; Fullerton, CA; Gilden, D; Huskamp, HA; Soumerai, SB; Zhang, F, 2012) |
| " The case of gabapentin use in bipolar disorder provides an opportunity to study the roles of marketing, clinical evidence, and prior authorization (PA) policy on off-label medication use." | 3.76 | The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. ( Busch, AB; Frank, RG; Fullerton, CA, 2010) |
| "We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports." | 3.75 | Outcome reporting in industry-sponsored trials of gabapentin for off-label use. ( Bero, L; Dickersin, K; Scherer, RW; Vedula, SS, 2009) |
| " One example is the pharmaceutical marketing to promote off-label use of gabapentin (Neurontin) for the treatment of bipolar disorder, the legality of which was later addressed in a major lawsuit by the National Association of Attorneys General." | 3.74 | Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder. ( Carey, TS; Evans, WD; Kreps, G; Linden, T; Melvin, CL; Oldham, J; Ranney, LM, 2008) |
| "To determine if gabapentin is effective in monotherapy or add-on treatment of non-refractory bipolar disorder in open prospective treatment." | 3.71 | Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. ( Ghaemi, SN; Goodwin, FK, 2001) |
| "The aim of the present study was to assess the efficacy of adjunctive gabapentin (GBP) in the treatment of patients with intellectual disability (ID) and bipolar spectrum disorders." | 3.71 | Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders. ( Carpiniello, B; Carta, MG; Dessì, I; Hardoy, MC; Hardoy, MJ, 2001) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 3.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "Gabapentin appears to be somewhat effective as add-on treatment in a subgroup of patients with mood disorders in a naturalistic setting." | 3.70 | Gabapentin treatment of mood disorders: a preliminary study. ( Desai, SP; Ghaemi, SN; Goodwin, FK; Katzow, JJ, 1998) |
| "To evaluate the efficacy of gabapentin as an adjunctive treatment for bipolar disorder in both depressed and manic phases." | 3.70 | Gabapentin as an adjunctive treatment in bipolar disorder. ( Hasey, GM; Joffe, RT; MacQueen, GM; Marriott, M; Patelis Siotis, I; Robb, JC; Young, LT, 1999) |
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 3.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| " This study examined the single-dose pharmacokinetic profiles of Li in 13 patients receiving placebo and then steady-state gabapentin (mean daily dose: 3,646." | 2.69 | Gabapentin does not alter single-dose lithium pharmacokinetics. ( Corá-Locatelli, G; Dunn, RT; Frye, MA; Grothe, D; Ketter, TA; Kimbrell, TA; Piscitelli, S; Post, RM; Vanderham, E, 1998) |
| "Gabapentin was effective in the treatment of mania and hypomania in patients with bipolar and schizoaffective disorders." | 2.69 | Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. ( Cabras, PL; Carta, MG; Hardoy, MC; Hardoy, MJ, 1999) |
| "Gabapentin is a new adjunctive medication to antiseizure therapies." | 2.69 | Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. ( DeMet, EM; Green, C; Maris, DE; Sokolski, KN, 1999) |
| "Gabapentin was well tolerated by all patients, with the most common side-effect being sedation." | 2.69 | Gabapentin in the acute treatment of refractory bipolar disorder. ( Altshuler, LL; Brown, ES; Denicoff, K; Frye, M; Gitlin, M; Goodman, R; Hwang, S; Keck, PE; Kupka, R; Leverich, G; McElroy, SL; Nolen, W; Post, R; Suppes, T, 1999) |
| "We examined systematic adverse events (AEs) in Part 1 (of 2) of a study describing the assessment and reporting of AEs in clinical trials." | 2.61 | Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "We examined 21 trials of gabapentin for neuropathic pain (52 sources) and seven trials of quetiapine for bipolar depression (80 sources) using data from the Multiple Data Sources study." | 2.61 | Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. ( Bertizzolo, L; Canner, JK; Cowley, T; Dickersin, K; Doshi, P; Ehmsen, J; Fusco, N; Gresham, G; Guo, N; Haythornthwaite, JA; Heyward, J; Hong, H; Li, T; Mayo-Wilson, E; Payne, JL; Pham, D; Rosman, L; Stuart, EA; Suarez-Cuervo, C; Tolbert, E; Twose, C; Vedula, S, 2017) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2017) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "Lamotrigine has demonstrated efficacy in both acute bipolar depression and maintenance efficacy in rapid cycling bipolar patients, especially those patients with bipolar II disorder, which is principally manifested as depression." | 2.41 | Novel treatments for bipolar disorder. ( Bowden, CL, 2001) |
| "Topiramate has shown encouraging results in both depressed and manic bipolar patients, and it may also promote weight loss." | 2.41 | Bipolar disorders and the effectiveness of novel anticonvulsants. ( Calabrese, JR; Kimmel, SE; Rapport, DJ; Shelton, MD, 2002) |
| "The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common." | 2.41 | Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000) |
| " One general rule that may reduce the risks of toxic drug interactions is to add medication to the patient's current regimen in modest doses and increase the dose slowly." | 2.40 | Mood stabilizer combinations: a review of safety and efficacy. ( Freeman, MP; Stoll, AL, 1998) |
| " Different methods for reporting adverse events across trials or across sources for a single trial may produce inconsistent information about the adverse events associated with interventions." | 1.51 | Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| " Past reports have suggested that some withdrawal symptoms can present after 1-2 days upon abrupt discontinuation of gabapentin after chronic use within young to middle-aged patients." | 1.33 | Gabapentin withdrawal syndrome in the presence of a taper. ( Hranicky, D; Jacob, Nj; Lark, T; Tran, KT, 2005) |
| "Gabapentin appears to be a safe and effective treatment in geriatric mania when combined with antipsychotic medications or valproate." | 1.32 | Gabapentin in geriatric mania. ( Devanand, DP; Mehta, R; Sethi, MA, 2003) |
| "Gabapentin is a relatively new anticonvulsant indicated for adjunctive therapy in the treatment of partial seizures, with and without secondary generalization, in adults with epilepsy." | 1.31 | Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin. ( Brannon, GE; Rolland, PD, 2000) |
| "Gabapentin is an anticonvulsant drug released in the United States in 1993 for use as adjunctive therapy in refractory partial epilepsy." | 1.31 | Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. ( Bailey, K; Hamrin, V, 2001) |
| " Dosage and side effects were noted." | 1.30 | Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. ( Knoll, J; Stegman, K; Suppes, T, 1998) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 1.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "Gabapentin is a new antiepileptic drug with an unknown mechanism of action and very favorable pharmacokinetic and safety profiles." | 1.30 | Gabapentin in the treatment of adolescent mania: a case report. ( Casuto, LS; Keck, PE; Soutullo, CA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (38.05) | 18.2507 |
| 2000's | 50 (44.25) | 29.6817 |
| 2010's | 17 (15.04) | 24.3611 |
| 2020's | 3 (2.65) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, JSW | 1 |
| Atkinson, LZ | 2 |
| Al-Juffali, N | 1 |
| Awad, A | 2 |
| Geddes, JR | 2 |
| Tunbridge, EM | 1 |
| Harrison, PJ | 2 |
| Cipriani, A | 2 |
| Saul, H | 3 |
| Gursul, D | 3 |
| Cassidy, S | 3 |
| Harrison, P | 3 |
| Mayo-Wilson, E | 7 |
| Fusco, N | 7 |
| Hong, H | 6 |
| Li, T | 7 |
| Canner, JK | 5 |
| Dickersin, K | 9 |
| Prisciandaro, JJ | 1 |
| Mellick, W | 1 |
| Squeglia, LM | 1 |
| Hix, S | 1 |
| Arnold, L | 1 |
| Tolliver, BK | 1 |
| Houghton, KT | 1 |
| Forrest, A | 1 |
| Stockton, S | 1 |
| Bertizzolo, L | 1 |
| Cowley, T | 2 |
| Doshi, P | 2 |
| Ehmsen, J | 2 |
| Gresham, G | 2 |
| Guo, N | 1 |
| Haythornthwaite, JA | 1 |
| Heyward, J | 2 |
| Pham, D | 1 |
| Payne, JL | 2 |
| Rosman, L | 2 |
| Stuart, EA | 2 |
| Suarez-Cuervo, C | 2 |
| Tolbert, E | 2 |
| Twose, C | 2 |
| Vedula, S | 2 |
| Lähteenvuo, M | 1 |
| Tanskanen, A | 1 |
| Taipale, H | 1 |
| Hoti, F | 1 |
| Vattulainen, P | 1 |
| Vieta, E | 4 |
| Tiihonen, J | 1 |
| Leith, WM | 1 |
| Lambert, WE | 1 |
| Boehnlein, JK | 1 |
| Freeman, MD | 1 |
| Hutfless, S | 1 |
| Lock, D | 1 |
| Haythornthwaite, J | 1 |
| Singh, S | 1 |
| Melvin, CL | 4 |
| Carey, TS | 3 |
| Goodman, F | 2 |
| Oldham, JM | 2 |
| Williams, JW | 2 |
| Ranney, LM | 4 |
| Whitener, L | 1 |
| Morgan, LC | 1 |
| Kish-Doto, J | 1 |
| Evans, WD | 2 |
| Squire, C | 1 |
| Williams, P | 1 |
| Kreps, G | 1 |
| Linden, T | 1 |
| Oldham, J | 1 |
| Vedula, SS | 2 |
| Bero, L | 1 |
| Scherer, RW | 1 |
| Rosa, AR | 1 |
| Fountoulakis, K | 1 |
| Siamouli, M | 1 |
| Gonda, X | 1 |
| Fullerton, CA | 2 |
| Busch, AB | 1 |
| Frank, RG | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Astaneh, AN | 1 |
| Rezaei, O | 1 |
| Chace, MJ | 1 |
| Zhang, F | 1 |
| Huskamp, HA | 1 |
| Gilden, D | 1 |
| Soumerai, SB | 1 |
| Perugi, G | 2 |
| Toni, C | 2 |
| Frare, F | 1 |
| Ruffolo, G | 2 |
| Moretti, L | 1 |
| Torti, C | 1 |
| Akiskal, HS | 1 |
| Wang, PW | 1 |
| Santosa, C | 1 |
| Schumacher, M | 1 |
| Winsberg, ME | 1 |
| Strong, C | 1 |
| Ketter, TA | 3 |
| Ernst, CL | 1 |
| Goldberg, JF | 2 |
| Shelton, RC | 1 |
| Gnanadesikan, M | 1 |
| Freeman, MP | 2 |
| Gelenberg, AJ | 1 |
| Carta, MG | 4 |
| Hardoy, MC | 4 |
| Hardoy, MJ | 4 |
| Grunze, H | 3 |
| Carpiniello, B | 2 |
| Sethi, MA | 1 |
| Mehta, R | 1 |
| Devanand, DP | 1 |
| Yatham, LN | 2 |
| Baldassano, CF | 1 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Wilson, MS | 1 |
| Muzina, DJ | 1 |
| Elhaj, O | 1 |
| Gajwani, P | 1 |
| Gao, K | 1 |
| Calabrese, JR | 3 |
| Tran, KT | 1 |
| Hranicky, D | 1 |
| Lark, T | 1 |
| Jacob, Nj | 1 |
| Howland, RH | 1 |
| Green, T | 1 |
| Shoval, G | 1 |
| Weizman, A | 1 |
| Manuel Goikolea, J | 1 |
| Martínez-Arán, A | 2 |
| Comes, M | 1 |
| Verger, K | 1 |
| Masramon, X | 1 |
| Sanchez-Moreno, J | 1 |
| Colom, F | 2 |
| Hellings, JA | 1 |
| Bialer, M | 1 |
| Silvia, RJ | 1 |
| Spitznas, AL | 1 |
| Sajatovic, M | 1 |
| Ramsay, E | 1 |
| Nanry, K | 1 |
| Thompson, T | 1 |
| Collins, JC | 1 |
| McFarland, BH | 1 |
| Short, C | 1 |
| Cooke, L | 1 |
| Hauck, A | 1 |
| Bhaumik, S | 1 |
| Stanton, SP | 1 |
| Keck, PE | 5 |
| McElroy, SL | 4 |
| Schaffer, CB | 2 |
| Schaffer, LC | 2 |
| Ryback, RS | 1 |
| Brodsky, L | 1 |
| Munasifi, F | 1 |
| Soutullo, CA | 2 |
| Kmetz, GF | 1 |
| Young, LT | 3 |
| Robb, JC | 2 |
| Patelis-Siotis, I | 1 |
| MacDonald, C | 1 |
| Joffe, RT | 2 |
| Stoll, AL | 1 |
| Sheldon, LJ | 1 |
| Ancill, RJ | 1 |
| Holliday, SG | 1 |
| Knoll, J | 1 |
| Stegman, K | 1 |
| Suppes, T | 4 |
| Casuto, LS | 1 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Strakowski, SM | 1 |
| Blinder, BJ | 1 |
| Bhat, S | 1 |
| Sanathara, VA | 1 |
| Ghaemi, SN | 3 |
| Katzow, JJ | 1 |
| Desai, SP | 1 |
| Goodwin, FK | 2 |
| Xie, X | 1 |
| Hagan, RM | 1 |
| Ferrier, IN | 1 |
| Dittert, S | 1 |
| Bungert, M | 1 |
| Erfurth, A | 2 |
| Frye, MA | 2 |
| Kimbrell, TA | 2 |
| Dunn, RT | 1 |
| Piscitelli, S | 1 |
| Grothe, D | 2 |
| Vanderham, E | 1 |
| Corá-Locatelli, G | 2 |
| Post, RM | 1 |
| Luckenbaugh, D | 1 |
| Constantino, C | 1 |
| Hatzimanolis, J | 1 |
| Lykouras, L | 1 |
| Oulis, P | 1 |
| Christodoulou, GN | 1 |
| Rosebush, PI | 1 |
| MacQueen, GM | 2 |
| Mazurek, MF | 1 |
| Cabras, PL | 2 |
| Letterman, L | 1 |
| Markowitz, JS | 1 |
| Labbate, LA | 1 |
| Rubey, RN | 1 |
| Lovell, RW | 1 |
| Amann, B | 1 |
| Normann, C | 1 |
| Walden, J | 1 |
| Sartini, S | 1 |
| Simonini, E | 1 |
| Akiskal, H | 1 |
| Hasey, GM | 1 |
| Patelis Siotis, I | 1 |
| Marriott, M | 1 |
| Bowden, CL | 2 |
| Mitchell, P | 1 |
| Magnus, L | 1 |
| Botts, SR | 1 |
| Raskind, J | 1 |
| Brown, ES | 2 |
| Hong, SC | 1 |
| Sokolski, KN | 1 |
| Green, C | 1 |
| Maris, DE | 1 |
| DeMet, EM | 1 |
| Leweke, FM | 1 |
| Bauer, J | 1 |
| Elger, CE | 1 |
| Chaudron, LH | 1 |
| Jefferson, JW | 1 |
| Brannon, GE | 1 |
| Rolland, PD | 1 |
| Greenberg, DB | 1 |
| Jonasch, E | 1 |
| Gadd, MA | 1 |
| Ryan, BF | 1 |
| Everett, JR | 1 |
| Sober, AJ | 1 |
| Mihm, MA | 1 |
| Tanabe, KK | 1 |
| Ott, M | 1 |
| Haluska, FG | 1 |
| Bennett, J | 1 |
| Goldman, WT | 1 |
| Nieto, E | 1 |
| Reinares, M | 1 |
| Benabarre, A | 1 |
| Gastó, C | 1 |
| Janowsky, DS | 1 |
| Nemeroff, CB | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Pande, AC | 1 |
| Crockatt, JG | 1 |
| Janney, CA | 1 |
| Werth, JL | 1 |
| Tsaroucha, G | 1 |
| Montes, JM | 1 |
| Ferrando, L | 1 |
| Chengappa, KN | 2 |
| Rathore, D | 1 |
| Levine, J | 2 |
| Atzert, R | 1 |
| Solai, L | 1 |
| Parepally, H | 1 |
| Levin, H | 1 |
| Moffa, N | 1 |
| Delaney, J | 1 |
| Brar, JS | 1 |
| Altshuler, LL | 1 |
| Denicoff, K | 1 |
| Frye, M | 1 |
| Gitlin, M | 1 |
| Hwang, S | 1 |
| Goodman, R | 1 |
| Leverich, G | 1 |
| Nolen, W | 1 |
| Kupka, R | 1 |
| Post, R | 1 |
| Dessì, I | 1 |
| Ginsberg, DL | 1 |
| Sussman, N | 2 |
| Burdick, KE | 1 |
| Pinninti, NR | 1 |
| Mahajan, DS | 1 |
| Ko, JY | 1 |
| Hamrin, V | 1 |
| Bailey, K | 1 |
| Maidment, ID | 1 |
| Robillard, M | 1 |
| Conn, D | 1 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Kimmel, SE | 1 |
| Gershon, S | 1 |
| Hurley, SC | 1 |
| Kusumakar, V | 1 |
| Rao, R | 1 |
| Scarrow, G | 1 |
| Kroeker, G | 1 |
| Sachs, GS | 1 |
| Cosgrove, VE | 1 |
| Biancosino, B | 1 |
| Facchi, A | 1 |
| Marmai, L | 1 |
| Grassi, L | 1 |
| Macdonald, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin for Bipolar & Cannabis Use Disorders[NCT03334721] | Phase 2 | 23 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| The Effects of Short-term Lithium Administration on Striatal Reward Processing and Prefrontal Control During Reappraisal in Healthy Volunteers[NCT03965247] | 37 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial[NCT01255878] | 20 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness[NCT00015769] | Phase 2 | 30 participants | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy. (NCT03334721)
Timeframe: Day 5 of each experimental condition
| Intervention | Institutional Units (Mean) | |
|---|---|---|
| GABA (randomization order 1, gabapentin 1st) | GABA (randomization order 2, placebo 1st) | |
| Gabapentin | 2.625 | 2.609 |
| Placebo Oral Capsule | 2.696 | 2.720 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
46 reviews available for gabapentin and Bipolar Disorder
| Article | Year |
|---|---|
Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
Topics: Amines; Anxiety; Bipolar Disorder; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; | 2017 |
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.
Topics: Amines; Bias; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Effects an | 2008 |
Gabapentin in the treatment of mental illness: the echo chamber of the case series.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Conflict of Interest; Cyclohexanecarboxylic Acids; Drug E | 2008 |
Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cy | 2011 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
Antidepressant properties of anticonvulsant drugs for bipolar disorder.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Carbamazepine; C | 2003 |
Treating bipolar depression.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2003 |
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2003 |
The clinical use of gabapentin in bipolar spectrum disorders.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2003 |
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
[The treatment of mood stabilizers in children and adolescents suffering from bipolar affective disorder].
Topics: Adolescent; Adult; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Child; Cyclohexaneca | 2005 |
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Topics: Amines; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug | 2006 |
Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2007 |
Mood stabilizer combinations: a review of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Calcium Channel Blockers; | 1998 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clinical T | 1998 |
Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.
Topics: Acetates; Action Potentials; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipol | 1998 |
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinic | 1998 |
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti | 1999 |
Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Aged; Amines; Analysis of Variance; Antidepressive Agents; | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Nonepileptic uses of gabapentin.
Topics: Acetates; Amines; Analgesics; Antimanic Agents; Antiparkinson Agents; Bipolar Disorder; Clinical Tri | 1999 |
Gabapentin and lamotrigine in bipolar disorder.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecar | 1999 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antimanic Agents; Antineoplastic Agents; Bipolar Disor | 2000 |
New treatments of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Clinical Tri | 1999 |
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamaz | 2000 |
Novel treatments for bipolar disorder.
Topics: Acetates; Amines; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Gabapentin treatment for bipolar disorders.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2001 |
Bipolar disorders and the effectiveness of novel anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 2002 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
Bipolar disorder: current treatments and new strategies.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 1998 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Cyc | 2002 |
19 trials available for gabapentin and Bipolar Disorder
| Article | Year |
|---|---|
Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.
Topics: Adolescent; Adult; Bipolar Disorder; Cigarette Smoking; Double-Blind Method; Female; Gabapentin; gam | 2022 |
Adjunctive treatment with gabapentin in bipolar patients during acute mania.
Topics: Acute Disease; Age Distribution; Amines; Analysis of Variance; Antimanic Agents; Bipolar Disorder; C | 2012 |
Gabapentin augmentation therapy in bipolar depression.
Topics: Acetates; Adult; Amines; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cycloh | 2002 |
A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Th | 2006 |
Much improved outcome with gabapentin-divalproex combination in adults with bipolar disorders and developmental disabilities.
Topics: Adolescent; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Developm | 2006 |
Gabapentin in the treatment of bipolar disorder.
Topics: Acetates; Adult; Ambulatory Care; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic A | 1997 |
A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Affect; Amines; Anticonvulsants; Bipolar Disorder; Cyclohe | 1997 |
Gabapentin does not alter single-dose lithium pharmacokinetics.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Depression; Doubl | 1998 |
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study.
Topics: Acetates; Acute Disease; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agent | 1999 |
[Gabapentin in the treatment of mania].
Topics: Acetates; Amines; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cyclohexaneca | 1999 |
Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states.
Topics: Acetates; Adjuvants, Pharmaceutic; Adult; Aged; Amines; Analysis of Variance; Antidepressive Agents; | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology.
Topics: Acetates; Adult; Affect; Aged; Ambulatory Care; Amines; Antidepressive Agents; Bipolar Disorder; Cyc | 1999 |
Adjunctive gabapentin treatment of bipolar disorder.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic | 2000 |
Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic | 2000 |
Topiramate as add-on treatment for patients with bipolar mania.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Body Mass Index; | 1999 |
Gabapentin in the acute treatment of refractory bipolar disorder.
Topics: Acetates; Acute Disease; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Ac | 1999 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
52 other studies available for gabapentin and Bipolar Disorder
| Article | Year |
|---|---|
Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.
Topics: Adverse Drug Reaction Reporting Systems; Bipolar Disorder; Gabapentin; Humans; Information Dissemina | 2019 |
Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).
Topics: Amines; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Data Collection; Ga | 2018 |
Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.
Topics: Administration, Oral; Adult; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug The | 2018 |
The association between gabapentin and suicidality in bipolar patients.
Topics: Adult; Age Factors; Antimanic Agents; Bipolar Disorder; Comorbidity; Female; Gabapentin; Humans; Lit | 2019 |
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Data Interp | 2015 |
Patterns of prescribing antiepileptic drugs for bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Eff | 2008 |
Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.
Topics: Advertising; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Evidence-Based | 2008 |
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2009 |
The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.
Topics: Adolescent; Adult; Amines; Anti-Anxiety Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Evide | 2010 |
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label | 2011 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |
Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Compensation and Redress; Cyclohexanecarboxylic Acids; Dr | 2012 |
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
Topics: Acetates; Adult; Aged; Alcoholism; Amines; Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bip | 2002 |
Gabapentin in geriatric mania.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cycl | 2003 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Amines; Antimanic Agents; Antiviral Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Ther | 2004 |
Gabapentin withdrawal syndrome in the presence of a taper.
Topics: Aged; Aged, 80 and over; Amines; Antimanic Agents; Bipolar Disorder; Chest Pain; Cyclohexanecarboxyl | 2005 |
Gabapentin-related changes in renal function: two case reports.
Topics: Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Diabetes Insipidus, Nephrog | 2007 |
Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Emerge | 2008 |
Hypomania induced by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Response Rela | 1995 |
Hypomania induced by gabapentin.
Topics: Acetates; Affect; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Electroenc | 1995 |
Treatment of acute mania with gabapentin.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1997 |
Gabapentin in bipolar disorder.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic | 1997 |
Acute treatment of bipolar depression with gabapentin.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1997 |
Gabapentin in geriatric psychiatry patients.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Bipolar Disorder; Cyc | 1998 |
Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Respon | 1998 |
Gabapentin in the treatment of adolescent mania: a case report.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cyclohexanecarbox | 1998 |
Advances in mood stabilizing medications.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Cyc | 1998 |
Gabapentin treatment of mood disorders: a preliminary study.
Topics: Acetates; Adolescent; Adult; Aged; Ambulatory Care; Amines; Anticonvulsants; Antidepressive Agents; | 1998 |
Renal impairment as a possible side effect of gabapentin. A single case report.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Thera | 1998 |
Possible gabapentin-induced thyroiditis.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxyl | 1999 |
Gabapentin as monotherapy in the treatment of acute mania.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Aci | 1999 |
Catatonia following gabapentin withdrawal.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Gabapentin | 1999 |
Gabapentin-induced ejaculatory failure and anorgasmia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Ejaculation | 1999 |
Mood stabilizer combinations for bipolar disorder.
Topics: Acetates; Adolescent; Age Factors; Amines; Antimanic Agents; Bipolar Disorder; Child; Cyclohexanecar | 1999 |
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar | 1999 |
Gabapentin as an adjunctive treatment in bipolar disorder.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Thera | 1999 |
Antidepressant-induced bruxism successfully treated with gabapentin.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Bipolar Disorder; B | 1999 |
Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment.
Topics: Acetates; Acute Disease; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Ac | 1999 |
Manic episode due to gabapentin treatment.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Gab | 1999 |
Anorgasmia in a patient with bipolar disorder type 1 treated with gabapentin.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin | 2000 |
Gabapentin for treatment of bipolar and schizoaffective disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Ga | 1997 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Gabapentin-induced anorgasmia as a cause of noncompliance in a bipolar patient.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin | 2001 |
Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Comorbidity; Cyclohexanecarboxylic Acid | 2001 |
Gabapentin treatment of the non-refractory bipolar spectrum: an open case series.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Depressive | 2001 |
Gabapentin as prophylaxis against steroid-induced mania.
Topics: Acetates; Amines; Anti-Inflammatory Agents; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxyli | 2001 |
Gabapentin-associated aggression.
Topics: Acetates; Adult; Aggression; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids | 2001 |
Quetiapine-related tardive dyskinesia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxy | 2001 |
Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder.
Topics: Acetates; Amines; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 2001 |
Gabapentin use in geriatric patients with depression and bipolar illness.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarbo | 2001 |
Gabapentin treatment of impulsive-aggressive behaviour.
Topics: Acetates; Adult; Aggression; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids | 2002 |